Providing stock analysis for investors of the Canadian junior markets
Fresh off a US$900 million settlement agreement, Biogen, Inc (Nasdaq: BIIB) announced positive topline results from the phase 3 study
Read more
Biogen, Inc (NASDAQ: BIIB) has reached a US$900 million deal to resolve a long-running whistleblower lawsuit concerning its multiple sclerosis
Read more
Biogen Inc (NASDAQ: BIIB) appears to be facing issues related to its executive team. The firm this morning indicated that
Read more
The Samsung Group is reportedly in negotiations to acquire biotech firm Biogen (Nasdaq: BIIB). The US firm approached the South Korean
Read more
This morning Biogen (NASDAQ:BIIB) received approval from the FDA for their Alzheimer’s drug aducanumab. The FDA decision marks the first
Read more